Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 1
2008 7
2009 12
2010 35
2011 37
2012 51
2013 61
2014 50
2015 33
2016 14
2017 11
2018 16
2019 13
2020 6
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 20498238

303 results
Results by year
Filters applied: . Clear all
Page 1
Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Rhee EP, Laliberte KA, Niles JL. Rhee EP, et al. Clin J Am Soc Nephrol. 2010 Aug;5(8):1394-400. doi: 10.2215/CJN.08821209. Epub 2010 May 24. Clin J Am Soc Nephrol. 2010. PMID: 20498238 Free PMC article.
Rituximab treatment for vasculitis.
Jayne D. Jayne D. Clin J Am Soc Nephrol. 2010 Aug;5(8):1359-62. doi: 10.2215/CJN.05500610. Epub 2010 Jul 29. Clin J Am Soc Nephrol. 2010. PMID: 20671223 Free article. No abstract available.
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR. Smith RM, et al. Arthritis Rheum. 2012 Nov;64(11):3760-9. doi: 10.1002/art.34583. Arthritis Rheum. 2012. PMID: 22729997 Free article.
[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D, Vangelista A, Pani A. Roccatello D, et al. G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. G Ital Nefrol. 2011. PMID: 22028261 Review. Italian.
Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, Niles JL. Pendergraft WF 3rd, et al. Clin J Am Soc Nephrol. 2014 Apr;9(4):736-44. doi: 10.2215/CJN.07340713. Epub 2014 Mar 13. Clin J Am Soc Nephrol. 2014. PMID: 24626432 Free PMC article.
Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R, Ljevak M, Vikgren J, Bokarewa M. Pullerits R, et al. Scand J Immunol. 2012 Oct;76(4):411-20. doi: 10.1111/j.1365-3083.2012.02747.x. Scand J Immunol. 2012. PMID: 22823472 Free article.
B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. Gómez-Puerta JA, et al. Autoimmun Rev. 2012 Jul;11(9):646-52. doi: 10.1016/j.autrev.2011.11.007. Epub 2011 Nov 21. Autoimmun Rev. 2012. PMID: 22146313 Review.
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Stasi R, et al. Rheumatology (Oxford). 2006 Nov;45(11):1432-6. doi: 10.1093/rheumatology/kel098. Epub 2006 Apr 21. Rheumatology (Oxford). 2006. PMID: 16632482 Clinical Trial.
[Rituximab for the treatment of ANCA associated vasculitis: the future today?].
Alba MA, Flores-Suárez LF. Alba MA, et al. Reumatol Clin. 2011 Dec;7 Suppl 3:S41-6. doi: 10.1016/j.reuma.2011.10.006. Epub 2011 Nov 23. Reumatol Clin. 2011. PMID: 22115869 Free article. Review. Spanish.
ANCA vasculitis: time for a change in treatment paradigm? Not yet.
Ntatsaki E, Mooney J, Watts RA. Ntatsaki E, et al. Rheumatology (Oxford). 2011 Jun;50(6):1019-24. doi: 10.1093/rheumatology/ker002. Epub 2011 Feb 3. Rheumatology (Oxford). 2011. PMID: 21292735 Review.
303 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page